Baseline characteristics for patients with PCL treated with ide-cel and cilta-cel
| Parameter . | Overall (N = 34) . | Ide-cel (n = 19) . | Cilta-cel (n = 15) . |
|---|---|---|---|
| Age, mean (range), y | 59 (30-76) | 61 (44-76) | 55 (30-70) |
| Sex, n (%) | |||
| Male | 22 (65) | 12 (63) | 10 (67) |
| Female | 12 (35) | 7 (37) | 5 (33) |
| Race, n (%) | |||
| White | 30 (88) | 17 (89) | 13 (87) |
| Black | 3 (9) | 1 (5) | 2 (13) |
| Other | 1 (3) | 1 (5) | 0 (0) |
| ECOG, n (%) | |||
| ECOG score of 0-1 | 30 (88) | 18 (95) | 12 (80) |
| ECOG score of ≥2 | 3 (9) | 1 (5) | 2 (13) |
| ECOG unknown | 1 (3) | 0 (0) | 1 (7) |
| PCL subtype, n (%) | |||
| Relapsed pPCL | 14 (41) | 7 (37) | 7 (47) |
| sPCL | 11 (32) | 10 (53) | 1 (7) |
| Unknown PCL subtype | 9 (27) | 2 (11) | 7 (47) |
| R-ISS, n (%) | |||
| R-ISS stage I | 4 (12) | 1 (5) | 3 (20) |
| R-ISS stage II | 18 (53) | 13 (68) | 5 (33) |
| R-ISS stage III | 5 (15) | 2 (11) | 3 (20) |
| R-ISS stage unknown | 7 (20) | 3 (16) | 4 (27) |
| High-risk cytogenetics, n (%) | 26 (76) | 18 (95) | 8 (53) |
| High-risk cytogenetics unknown, n (%) | 2 (6) | 0 (0) | 2 (13) |
| Deletion 17p | 12 (35) | 8 (42) | 4 (27) |
| t (4;14) | 4 (12) | 4 (21) | 0 (0) |
| t (4;14) unknown | 2 (6) | 1 (5) | 1 (7) |
| t (14;16) | 4 (12) | 2 (11) | 2 (13) |
| t (14;16) unknown | 3 (9) | 1 (5) | 2 (13) |
| 1q gain/amp | 16 (47) | 11 (58) | 5 (33) |
| 1q gain/amp unknown | 4 (12) | 2 (11) | 2 (13) |
| Double hit | 9 (26) | 6 (32) | 3 (20) |
| Triple hit | 1 (3) | 1 (5) | 0 (0) |
| Extramedullary disease, n (%) | 10 (29) | 6 (32) | 4 (27) |
| Previous auto-HSCT, n (%) | 31 (91) | 18 (95) | 13 (87) |
| TCR, n (%) | 25 (74) | 15 (79) | 10 (67) |
| TCR unknown, n (%) | 5 (15) | 4 (21) | 1 (7) |
| PDR, n (%) | 11 (32) | 7 (37) | 4 (27) |
| PDR unknown, n (%) | 5 (15) | 4 (21) | 1 (7) |
| Previous lines of therapy, median (IQR) | 5 (4-6) | 6 (5-7) | 5 (4-5) |
| Ferritin before LD, median (IQR), μg/L | 416 (175-1682) | 470 (230-1569) | 416 (168-1482) |
| Ferritin before LD unknown, n (%) | 1 (3) | 1 (5) | 0 (0) |
| CRP, median (IQR), mg/L | 2.8 (0.4-5.6) | 2.4 (0.4-4.9) | 2.9 (0.6-6.6) |
| CRP unknown, n (%) | 1 (3) | 1 (5) | 0 (0) |
| BMPC ≥50%, n (%) | 11 (32) | 9 (47) | 2 (13) |
| BMPC ≥50% unknown, n (%) | 3 (9) | 0 (0) | 3 (20) |
| Parameter . | Overall (N = 34) . | Ide-cel (n = 19) . | Cilta-cel (n = 15) . |
|---|---|---|---|
| Age, mean (range), y | 59 (30-76) | 61 (44-76) | 55 (30-70) |
| Sex, n (%) | |||
| Male | 22 (65) | 12 (63) | 10 (67) |
| Female | 12 (35) | 7 (37) | 5 (33) |
| Race, n (%) | |||
| White | 30 (88) | 17 (89) | 13 (87) |
| Black | 3 (9) | 1 (5) | 2 (13) |
| Other | 1 (3) | 1 (5) | 0 (0) |
| ECOG, n (%) | |||
| ECOG score of 0-1 | 30 (88) | 18 (95) | 12 (80) |
| ECOG score of ≥2 | 3 (9) | 1 (5) | 2 (13) |
| ECOG unknown | 1 (3) | 0 (0) | 1 (7) |
| PCL subtype, n (%) | |||
| Relapsed pPCL | 14 (41) | 7 (37) | 7 (47) |
| sPCL | 11 (32) | 10 (53) | 1 (7) |
| Unknown PCL subtype | 9 (27) | 2 (11) | 7 (47) |
| R-ISS, n (%) | |||
| R-ISS stage I | 4 (12) | 1 (5) | 3 (20) |
| R-ISS stage II | 18 (53) | 13 (68) | 5 (33) |
| R-ISS stage III | 5 (15) | 2 (11) | 3 (20) |
| R-ISS stage unknown | 7 (20) | 3 (16) | 4 (27) |
| High-risk cytogenetics, n (%) | 26 (76) | 18 (95) | 8 (53) |
| High-risk cytogenetics unknown, n (%) | 2 (6) | 0 (0) | 2 (13) |
| Deletion 17p | 12 (35) | 8 (42) | 4 (27) |
| t (4;14) | 4 (12) | 4 (21) | 0 (0) |
| t (4;14) unknown | 2 (6) | 1 (5) | 1 (7) |
| t (14;16) | 4 (12) | 2 (11) | 2 (13) |
| t (14;16) unknown | 3 (9) | 1 (5) | 2 (13) |
| 1q gain/amp | 16 (47) | 11 (58) | 5 (33) |
| 1q gain/amp unknown | 4 (12) | 2 (11) | 2 (13) |
| Double hit | 9 (26) | 6 (32) | 3 (20) |
| Triple hit | 1 (3) | 1 (5) | 0 (0) |
| Extramedullary disease, n (%) | 10 (29) | 6 (32) | 4 (27) |
| Previous auto-HSCT, n (%) | 31 (91) | 18 (95) | 13 (87) |
| TCR, n (%) | 25 (74) | 15 (79) | 10 (67) |
| TCR unknown, n (%) | 5 (15) | 4 (21) | 1 (7) |
| PDR, n (%) | 11 (32) | 7 (37) | 4 (27) |
| PDR unknown, n (%) | 5 (15) | 4 (21) | 1 (7) |
| Previous lines of therapy, median (IQR) | 5 (4-6) | 6 (5-7) | 5 (4-5) |
| Ferritin before LD, median (IQR), μg/L | 416 (175-1682) | 470 (230-1569) | 416 (168-1482) |
| Ferritin before LD unknown, n (%) | 1 (3) | 1 (5) | 0 (0) |
| CRP, median (IQR), mg/L | 2.8 (0.4-5.6) | 2.4 (0.4-4.9) | 2.9 (0.6-6.6) |
| CRP unknown, n (%) | 1 (3) | 1 (5) | 0 (0) |
| BMPC ≥50%, n (%) | 11 (32) | 9 (47) | 2 (13) |
| BMPC ≥50% unknown, n (%) | 3 (9) | 0 (0) | 3 (20) |
High-risk cytogenetics include del17P, t(4;14), t(14;16). The following parameters had missing data points (percentage of available information reflected): ECOG (97%), PCL subtype (74%), R-ISS stage (79%), t(4;14) (94%), t(14;16) (92%), 1q gain/amp (85%), ferritin prior LD (97%), CRP prior LD (97%), and BMPC (88%).
BMPC, bone marrow plasma cell; CRP, C-reactive protein; IQR, interquartile range; LD, lymphodepleting chemotherapy; PDR, pentadrug refractory; R-ISS, Revised International Staging System; TCR, triple-class refractory.